Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen
The shares have made a very decent start to life on AIM. Listed for 5p each, they are currently changing hands for 7.4p, having been as high as 8p.
The India-focused generator recently paid a maiden dividend.
There is more to the company than it's buy-and-build strategy - although the approach appears to be working well.
Revenues for the year to December 31 will be "slightly more than US$90mln", BATM said in a trading statement ahead of its prelims on March 8.
Abzena's technology is being used in a potential new treatment for anti-phospholipid syndrome, a disorder of the immune system that causes an increased risk of blood clots.
The regenerative medical devices specialist has been awarded an innovative technology contract from Vizient, the largest member-owned health care company in the US.
The University of Chester’s Thornton Science Park will be host to the breakthrough technology.
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.
A look at some City analysts view on Tuesday.
“Our key concern is that cash generation does not support [the] valuation,” the Wall Street investment bank said.